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Abstract
Introduction: Encapsulating peritoneal sclerosis (EPS) is a devastating complication of peritoneal dialysis (PD). The
pathogenesis is not exactly known and no preventive strategy or targeted medical therapy is available. CCN2 has both pro-
fibrotic and pro-angiogenic actions and appears an attractive target. Therefore, we studied peritoneal expression of CCN2,
as well as TGFb1 and VEGF, in different stages of peritoneal fibrosis.
Materials and methods: Sixteen PD patients were investigated and compared to 12 hemodialysis patients and four pre-
emptively transplanted patients. Furthermore, expression was investigated in 12 EPS patients in comparison with 13 PD and
12 non-PD patients without EPS. Peritoneal tissue was taken during kidney transplantation procedure or during EPS surgery.
In a subset of patients, CCN2 protein levels in peritoneal effluent and plasma were determined. Samples were examined by
qPCR, histology, immunohistochemistry, and ELISA.
Results: Peritoneal CCN2 expression was 5-fold higher in PD patients compared to pre-emptively transplanted patients (P,
0.05), but did not differ from hemodialysis patients. Peritoneal expression of TGFb1 and VEGF were not different between
the three groups; neither was peritoneal thickness. Peritoneum of EPS patients exhibited increased expression of CCN2 (35-
fold, P,0.001), TGFb1 (24-fold, P,0.05), and VEGF (77-fold, P,0.001) compared to PD patients without EPS. In EPS patients,
CCN2 protein was mainly localized in peritoneal endothelial cells and fibroblasts. CCN2 protein levels were significantly
higher in peritoneal effluent of EPS patients compared to levels in dialysate of PD patients (12.064.5 vs. 0.9160.92 ng/ml,
P,0.01), while plasma CCN2 levels were not increased.
Conclusions: Peritoneal expression of CCN2, TGFb1, and VEGF are significantly increased in EPS patients. In early stages of
peritoneal fibrosis, only CCN2 expression is slightly increased. Peritoneal CCN2 overexpression in EPS patients is a locally driven
response. The potential of CCN2 as biomarker and target for CCN2-inhibiting agents to prevent or treat EPS warrants further study.
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Introduction
Chronic treatment with peritoneal dialysis (PD) results in
morphological changes in the peritoneal membrane. These
alterations include progressive fibrosis and neo-angiogenesis and
are associated with increased solute transport and loss of
ultrafiltration [1–10]. Encapsulating peritoneal sclerosis (EPS)
could be considered as a severe, advanced form of peritoneal
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fibrosis for which a second hit is mandatory [11–13]. This
condition, for which no preventive strategy or targeted medical
therapy is available, is a significant threat to patients on PD with a
reported mortality of 25 to 55% [14,15].
The human pathogenesis of EPS is not fully understood, but
animal studies strongly suggest that both transforming growth
factor-b1 (TGFb1) and vascular endothelial growth factor (VEGF)
are key players in the early peritoneal membrane changes and are
potential targets for intervention [16–23]. This was recently
illustrated by Loureiro et al. [24], who demonstrated that
intraperitoneal administration of TGF-b1-blocking peptides to
mice exposed to PD fluid significantly decreased peritoneal fibrosis
and angiogenesis and improved peritoneal ultrafiltration.
Although this study suggests that TGFb1 inhibition could be a
tool to prevent or treat EPS, direct and chronic inhibition of
systemic TGFb1 activity is probably not desirable in humans given
the important role of TGFb1 in immune regulation and tumor
suppression [25–31]. In this respect, the main downstream pro-
fibrotic mediator of TGFb1 activity, connective tissue growth
factor (CCN2), might be a more attractive target. This protein,
which is also involved in neo-angiogenesis [32], is overexpressed in
a variety of fibrotic disorders [33–35] and some studies also suggest
a pathogenic role for CCN2 in the peritoneal membrane
alterations caused by long term PD [36–38].
Peritoneal biopsy studies in humans, which investigate the
expression of pro-fibrotic and pro-angiogenic factors including
CCN2, are scarce. In the current study, we investigated the
peritoneal gene expression of CCN2, TGFb1, and VEGF in
different stages of peritoneal fibrosis. We hypothesized that CCN2,
TGFb1, and VEGF are already upregulated in early stages of
peritoneal fibrosis and further overexpressed in EPS. For this
purpose, we compared peritoneal expression of these factors in PD
patients to PD naive patients with end stage kidney disease
(ESKD) and in EPS patients in comparison to PD patients without
EPS.
Materials and Methods
Study design
We performed two cross-sectional studies between October
2008 and September 2012. In study 1, we investigated peritoneal
CCN2, TGFb1, and VEGF gene expression and peritoneal
thickness in three groups of patients with ESKD. In study 2, we
determined peritoneal mRNA levels for CCN2, TGFb1, and
VEGF in EPS patients in comparison to two groups of patients
without EPS (PD patients and non-PD patients).
Study populations
Study 1. We obtained biopsies of the parietal peritoneum
during kidney transplant procedures performed in the University
Medical Center Utrecht in 16 PD patients, in 12 hemodialysis
(HD) patients, and in four patients who received a pre-emptive
kidney transplant. In PD patients, peritonitis was excluded at the
time of biopsy by effluent cell count of ,0.16109/L and negative
culture.
Study 2. We performed a study in collaboration with
Addenbrooke’s Hospital in Cambridge, UK, which is one of the
two referral centers in the UK for EPS surgery. Peritoneal tissue
was obtained in 12 consecutive EPS patients who underwent
surgery to resolve severe bowel obstruction. These EPS patients
were compared with 25 ESKD patients without EPS who
underwent kidney transplantation in the University Medical
Center Utrecht; 13 patients who were on PD (PD group) and 12
ESKD patients who were never treated with PD (non-PD
patients). None of these patients had symptoms of intestinal
obstruction or had macroscopic signs of EPS (evaluated during
kidney transplantation).
All EPS patients fulfilled the criteria for EPS developed by the
Ad Hoc Committee of the International Society for Peritoneal
Dialysis [39] and had severe clinical symptoms related to intestinal
obstruction in combination with radiological evidence. In all EPS
patients, the diagnosis was confirmed macroscopically. None of the
PD patients had peritonitis at the time of biopsy.
Demographic and clinical data were collected from all patients.
Both studies were conducted in accordance with the Declaration
of Helsinki and the Good Clinical Practice guidelines set by the
International Conference on Harmonization. Study protocols
were approved by the Ethics Committees of the University
Medical Center Utrecht and of the Addenbrooke’s Hospital. All
study participants provided written informed consent.
Sample collection and processing
Collection of peritoneal tissue during kidney transplantation was
done using a standardized procedure. In brief, a suture loop was
inserted through the outer layer of the parietal peritoneum. By
using the suture to lift the peritoneum, an ellipse of 2 cm in length
was excised and pinned onto a paraffin wax plate with the
mesothelial surface uppermost. Afterwards, the peritoneal cavity
was closed with a suture.
In EPS patients, peritoneal tissue was taken during a
decortication procedure which was performed to release obstruct-
ed small bowel segments. This sample included the falciform
ligament and adjacent parietal peritoneum since this is typically
excised and discarded.
Immediately after sampling, half of the biopsy was snap frozen
in liquid nitrogen for isolation of RNA. The other half was fixed
with 4% formaldehyde. After fixation for 24 hours at room
temperature, samples were routinely processed for light microsco-
py and embedded in paraffin.
For study 2, we collected plasma samples before the surgical
procedure whenever possible. If ascites fluid was present in EPS
patients during surgery, this was also collected for analysis. In PD
patients, a standard four-hour peritoneal equilibration test was
performed [40] with a 3.86% glucose solution just before
transplantation when time allowed this. Plasma and peritoneal
fluid samples were stored at 280uC.
Samples were examined by quantitative PCR, histology,
immunohistochemistry, and sandwich enzyme-linked immunosor-
bent assay (ELISA).
Quantitative PCR
Total RNA was extracted from frozen peritoneal tissue using
RNeasy columns (Qiagen, Venlo, The Netherlands). After cDNA
synthesis, determination of CCN2 (Hs00170014_m1), TGFb1
(Hs00998133_m1), and VEGF (Hs00900055_m1) mRNA levels
were assessed by quantitative real-time PCR using TaqMan Gene
Expression Assays with commercially pre-designed probe and
primers (Applied Biosystems, Foster City, CA, USA). TATA box
binding protein (TBP) (Hs00427620_m1) and glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) (Hs02758991_g1) were used
as internal reference in study 1 and 2, respectively.
Histological analysis
Peritoneal thickness was determined by measuring the thickness
of the submesothelial compact (SMC) zone on hematoxylin and
eosin stained formalin-fixed four-mm-thick tissue sections. The
SMC zone is the submesothelial interstitial layer between the basal
border of surface mesothelial cells and upper border of peritoneal
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adipose tissue. All biopsies were digitalized using a microscope
camera (Nikon Eclipse E800 microscope with DXM1200 digital
camera, Tokyo, Japan) and analyzed by image analysis software
(ImageJ 1.45, NIH, Bethesda, MY, USA). Peritoneal thickness was
measured perpendicular to the serosal surface at ten randomly
selected points by two independent, blinded examiners, and then
the average peritoneal thickness (APT) was calculated as described
by Honda et al. [9]. The mean of the two APT values obtained in
this fashion was used for further analysis.
CCN2 immunohistochemistry
To validate CCN2 expression at the protein level and to
determine its exact localization, CCN2 immunohistochemistry was
performed in EPS patients on four-mm-thick paraffin embedded
sections and compared to non-EPS PD patients. These samples
were treated with endogenous peroxidase block. Antigen retrieval
was achieved by predigestion with Protease XXIV (Sigma, St.
Louis, MO, USA). Sections were incubated with a goat-anti-
CCN2 antibody (sc-14939, Santa Cruz Biotechnology, Heidel-
berg, Germany), followed by rabbit-anti-goat IgG (Dako,
Glostrup, Denmark) and goat-anti-rabbit BrightVision-PO (Klini-
path, Duiven, Netherlands). Bound antibody was visualized with
NovaRed (Vector Laboratories, Burlingame, CA, USA).
CCN2 ELISA
Plasma and peritoneal fluid samples were thawed on the day of
use and any solids pelleted by centrifugation. Afterwards, the
supernatant was diluted 1:10 in assay buffer. CCN2 present in the
plasma or peritoneal fluid was then quantified using an ELISA as
previously reported [41]. Briefly, the ELISA plate was first coated
with CCN2 L-20 antibody, as a specific trapping antibody (sc-
14939, Santa Cruz Biotechnology Inc., Dallas, TX, USA). The
plates were incubated with sample or CCN2 standard and
afterwards washed before the addition of 20a anti-CCN2
antibody. After further washing, horseradish peroxidase-conjugat-
ed secondary antibody (goat anti-rabbit; Jackson ImmunoRe-
search, West Grove, PA, USA) was added, followed by horseradish
peroxidase substrate (Enhanced K-Blue TMB substrate, 308175;
Neogen Corp., Lexington, KY, USA). The color intensity was
allowed to develop, and read at 650 nm using a microplate reader.
All CCN2 levels are expressed as ng/ml.
Statistical analysis
Data are presented as mean 6 SD or median (interquartile
range). Difference between groups were analysed by one way
ANOVA or Kruskal-Wallis test where appropriate, with Bonfer-
roni correction or Dunn’s test for multiple post-hoc comparisons.
Spearman’s rank correlation test was used to assess correlation
coefficients.
For all comparisons, a P-value ,0.05 was considered to be
significant (two-tailed). Statistical analysis was performed using
GraphPad Prism software version 5.02 for Windows.
Results
Patient characteristics
The clinical characteristics of the study population are
summarized in table 1 and 2.
In study 1, none of the PD patients had a history of
ultrafiltration failure (UFF) and HD patients were predominantly
male. In study 2, EPS patients were younger (P,0.05) and had a
longer cumulative duration of PD (P,0.001) compared to PD
patients without EPS. At the time of diagnosis, none of the EPS
patients were treated with PD, nine were on HD and three had a
functioning kidney graft. Four EPS patients and none of the PD
patients without EPS had a known history of UFF.
Peritoneal CCN2, TGFb1, and VEGF gene expression and
peritoneal thickness in PD patients, HD patients, and
pre-emptively transplanted patients (study 1)
Peritoneal gene expression of CCN2 was 5-fold higher in PD
patients compared to pre-emptively transplanted patients (P,
0.05), but did not significantly differ from HD patients (figure 1A).
Peritoneal gene expression of TGFb1 and VEGF were not
significantly different between the three groups (figure 1B and 1C).
Peritoneal thickness also did not differ significantly between groups
(figure 2A). In PD patients, no correlation was found between
CCN2 gene expression and peritoneal thickness (figure 2B) or
between CCN2 gene expression and PD duration (figure 2C). Also
TGFb1 and VEGF gene expression did not correlate with
peritoneal thickness.
Peritoneal CCN2, TGFb1, and VEGF gene expression in
EPS patients and PD and non-PD patients without EPS
(study 2)
Peritoneal gene expression of CCN2 was 35-fold higher in EPS
patients compared to PD patients without EPS (P,0.001,
figure 3A). CCN2 gene expression did not differ between the
two groups of patients without EPS (figure 3A).
Peritoneal gene expression of TGFb1 and VEGF were also
higher in EPS patients compared to non-EPS PD patients (24-fold,
P,0.05 and 77-fold, P,0.001, respectively), while this did not
differ between the two groups of patients without EPS (figure 3B
and 3C).
Peritoneal CCN2 protein expression and CCN2 protein
concentrations in ascites and plasma of EPS patients
CCN2 immunohistochemistry could be performed on perito-
neal samples of six EPS patients. In agreement with the increased
CCN2 gene expression, we found a clear, prominent elevation in
CCN2 staining in EPS patients compared to PD patients without
EPS (n = 13) with localization mainly in endothelial cells and
interstitial fibroblasts (figure 4).
Mean CCN2 protein concentration in ascites of EPS patients
obtained in seven patients during surgery was 12.064.5 ng/ml.
These levels were approximately 12-fold higher than levels
measured in dialysate of four PD patients without EPS obtained
from a standard four-hour peritoneal equilibration test (mean
0.9160.92 ng/ml, P,0.01, figure 5A). In contrast, CCN2 protein
levels determined in plasma did not differ between patient groups
(40.4619.5 ng/ml in EPS versus 34.1616.5 ng/ml in PD without
EPS versus 23.7613.8 ng/ml in non-PD without EPS, P = 0.11,
figure 5B). It should be noted that plasma samples were obtained
in only six EPS patients.
Discussion
Our study shows markedly increased gene expression of CCN2
(35-fold), TGFb1 (24-fold), and VEGF (77-fold) in the peritoneal
membrane of EPS patients compared to PD patients without EPS.
In the latter group, we could at best demonstrate a very mildly (5-
fold) increased peritoneal gene expression of CCN2 in patients
with a median dialysis duration of 34 months compared to pre-
emptively transplanted patients with ESKD, while TGFb1 and
VEGF gene expression were not increased. Peritoneal CCN2
protein expression, which was also markedly increased in EPS
Peritoneal Overexpression of CCN2, TGFb1 and VEGF in EPS
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patients, was most prominent in endothelial cells and interstitial
fibroblasts.
EPS is the most severe complication of treatment with PD and
its pathogenesis is not exactly known. A two-hit theory has been
proposed, with long term PD itself and the chronic use of
bioincompatible PD solutions as first hits, leading to peritoneal
fibrosis and possibly UFF. Severe peritonitis, discontinuation of
PD or kidney transplantation have been proposed as second hits
provoking fulminant EPS [13,42].
Table 1. Baseline characteristics of patients in study 1.
Peritoneal dialysis
patients (n =16)
Hemodialysis patients
(n=12)
Pre-emptively transplanted
patients (n=4) P-value
Age (years) 56 (42–62) 57 (47–63) 43 (35–48) 0.10
Gender (F/M) 9/7 2/10 2/2 0.10
Cause of kidney disease
Glomerulonephritis 6 (37%) 5 (41%) 0 (0%)
Renal vascular disease 1 (6%) 0 (0%) 0 (0%)
Cystic kidney disease 4 (25%) 2 (17%) 3 (75%)
Diabetic nephropathy 0 (0%) 0 (0%) 0 (0%)
Congenital and hereditary
kidney disease
1 (6%) 0 (0%) 0 (0%)
Other 2 (13%) 2 (17%) 0 (0%)
Unknown 2 (13%) 3 (25%) 1 (25%)
Dialysis duration (months) 34 (12–55) 45 (6–60) N/A 0.82
Residual renal function (yes) 6 (38%) 5 (42%) 4 (100%) 0.07
History of peritonitis (yes) 8 (50%) N/A N/A
Ultrafiltration failure (yes) 0 (0%) N/A N/A
Data are median (IQR) or number of patients (%)
Abbreviations: F, female; M, male; N/A, not applicable.
doi:10.1371/journal.pone.0112050.t001
Table 2. Baseline characteristics of patients in study 2.
EPS patients (n =12)
Peritoneal dialysis
patients (n =13)
Non peritoneal dialysis
patients (n=12) P-value
Age (years) 47 (40–54) 56 (52–62) 52 (45–62) ,0.05*
Gender (F/M) 4/8 7/6 3/9 0.31
Cause of kidney disease
Glomerulonephritis 3 (25%) 3 (23%) 4 (33%)
Renal vascular disease 1 (8%) 0 (0%) 0 (0%)
Cystic kidney disease 1 (8%) 5 (38%) 4 (33%)
Diabetic nephropathy 3 (25%) 0 (0%) 0 (0%)
Congenital and hereditary
kidney disease
2 (17%) 1 (8%) 0 (0%)
Other 0 (0%) 1 (8%) 2 (17%)
Unknown 2 (17%) 3 (23%) 2 (17%)
PD duration (months) 67 (53–98) 26 (12–45) N/A ,0.001
History of peritonitis (yes) 7 (58%) 6 (46%) N/A 0.54
Ultrafiltration failure (yes) 4 (31%) 0 (0%) N/A ,0.05
Renal replacement therapy when EPS
Peritoneal dialysis 0 (0%) N/A N/A
Hemodialysis 9 (75%) N/A N/A
Kidney transplantation 3 (25%) N/A N/A
Data are median (IQR) or number of patients (%).
* EPS vs. PD.
Abbreviations: F, female; M, male; PD, peritoneal dialysis; EPS, encapsulating peritoneal sclerosis; N/A, not applicable.
doi:10.1371/journal.pone.0112050.t002
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Several in vitro and animal studies have focused on the
pathogenesis of peritoneal fibrosis and sclerosis. These preclinical
studies indicate that TGFb1 and VEGF are key players in the
development of both peritoneal fibrosis and EPS [16,19,21–24,43]
and that CCN2 expression in cultured human peritoneal
mesothelial cells (HPMCs) and peritoneal fibroblasts could be
induced by exposing these cells to PD solutions, glucose, glucose
degradation products, and advanced glycation end products
[36,37]. However, biopsy studies in humans investigating the role
of TGFb1, VEGF, and CCN2 in peritoneal fibrosis and EPS in
humans are scarce.
Using immunohistochemistry, Braun et al. studied the protein
expression of TGFb1, CCN2, and VEGF in the peritoneum of
nine EPS patients who underwent surgery for bowel obstruction
after a PD duration of 103632 months [44]. For comparison, they
studied patients on PD (n = 10, mean PD duration 19628 months)
and 10 non-renal surgical controls with normal peritoneum.
Peritoneal tissue was obtained in the PD patients during elective
surgery for hernias, leakage or catheter reinsertion. Compared to
the surgical controls, peritoneal TGFb1 was upregulated in
patients on PD and in EPS patients, but the expression between
the latter groups was not different. The peritoneal CCN2
expression was increased in PD patients compared to the surgical
controls but did not differ from that in EPS patients. Interestingly,
the peritoneal thickness in the PD patients without EPS was
considerable (,2000 mm) and comparable to that in EPS patients
(,2500 mm), indicating that the PD patients had a rather ‘‘sick’’
peritoneal membrane despite the relatively short PD duration.
This may explain the lack of difference in TGFb1 and CCN2
expression between PD patients and those suffering from EPS.
Despite this similarity in peritoneal damage in the EPS and non-
EPS groups in the study of Braun, the increase in VEGF
expression was much more pronounced in the EPS group,
pointing to an important role for this cytokine in the development
of EPS. In agreement with this observation, the increase in VEGF
mRNA expression was also more pronounced than that of TGFb1
or CCN2 in the EPS patients in our study.
In PD patients with UFF, but without EPS, Mizutani et al.
specifically investigated the peritoneal expression of CCN2 [38].
They studied the CCN2 mRNA levels in ESKD patients at the
time of PD catheter implantation (uremic controls, n = 26), in
incidental PD patients at the time of catheter removal for reasons
other than UFF (n = 23) and in patients with UFF (n = 7). The
peritoneal CCN2 mRNA expression in patients with UFF, who
Figure 1. Peritoneal CCN2, TGFb1, and VEGF gene expression in end stage kidney disease. Gene expression of CCN2 (1A), TGFb1 (1B),
and VEGF (1C) in peritoneum of peritoneal dialysis (PD), hemodialysis (HD), and pre-emptively transplanted patients. Mean6SD. * P,0.05 versus pre-
emptive.
doi:10.1371/journal.pone.0112050.g001
Figure 2. Peritoneal thickness, PD duration, and CCN2 expression in end stage kidney disease. Peritoneal thickness did not differ
between peritoneal dialysis (PD), hemodialysis (HD), and pre-emptively transplanted patients (2A). Mean 6SD. In PD patients no correlation was
found between CCN2 gene expression and peritoneal thickness (R =20.24, P = 0.36) (2B) and between CCN2 gene expression and PD duration (R =2
0.11, P = 0.67) (2C).
doi:10.1371/journal.pone.0112050.g002
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had been on PD for 9.4 years, was found to be increased 11.4-fold
compared to the uremic controls, who also had a less thickened
peritoneum than the UFF group (157 mm versus 308 mm).
Interestingly, the CCN2 gene expression as well as the peritoneal
thickness (155 mm) in the group of PD patients with normal
ultrafiltration, who had been on PD for a mean of 3.7 years, were
similar to that in the uremic control group, indicating that these
patients had sustained little peritoneal damage despite PD
treatment. This agrees with the very mild increase in CCN2 gene
expression observed in our non-EPS PD patients.
The results of the above mentioned studies and our findings
indicate that the fibrotic pathway involving TGFb1 and CCN2 is
markedly activated in the peritoneal tissues of patients with
advanced peritoneal damage, resulting in either UFF (CCN2 in
Mizutani’s study) or EPS (both factors in the Braun et al. study and
in ours). In addition, a very pronounced peritoneal upregulation of
VEGF seems to be specific for EPS patients (Braun et al. and
present study). In contrast, these growth factors are apparently not
or only mildly (CCN2 in present study) upregulated in patients
with a PD duration of 3 to 4 years who have a peritoneal thickness
comparable to that of uremic and HD patients. It is of note that
neither our study nor that of Mizutani et al. included a substantial
number of patients with a PD duration intermediate between the 3
to 4 years of the control patients and the longer interval after
which UFF or EPS develops. Therefore, it remains uncertain if
activation of the fibrotic pathway involving overexpression of
TGFb1 and CCN2 occurs gradually or is a relatively abrupt and
late phenomenon provoked by a second hit.
Our observation that both TGFb1 and CCN2 are highly
expressed in the peritoneum of EPS patients is in accordance with
the current view that CCN2 is induced by TGFb1 and acts as a
cofactor to enhance the fibrotic actions of TGFb1 [45–47]. The
close interaction between CCN2 and TGFb in the development of
EPS was clearly demonstrated in an experiment by Wang et al.
[46], in which only simultaneous intraperitoneal administration of
TGFb and CCN2 produced an EPS like phenotype in neonatal
mice, whereas administration of either cytokine alone failed to
produce any fibrosis. Although blocking of TGFb1 seems a
rational and effective approach to ameliorate peritoneal fibrosis
[24], this may be unwarranted in view of the important favourable
role that TGFb1 plays in cell immunity, proliferation and
differentiation [25–31]. Therefore, CCN2 may be a more
appropriate target to prevent or reduce peritoneal fibrosis. Using
small interfering RNA (siRNA) of CCN2, Liu et al. showed that
the expression of CCN2 and VEGF induced by TGFb1 can be
inhibited in cultured HPMCs [48]. The same group showed that
CCN2 knockdown using interference RNA also attenuated
TGFb1-induced extracellular matrix production and VEGF
expression in HPMCs [49]. Phase 2 studies have indicated that
EXC 001, an antisense oligonucleotide targeting CCN2, may be
efficacious in reducing hypertrophic scar formation following
surgery. Also, a humanized monoclonal antibody (FG-3019)
directed at CCN2 has undergone safety trials in patients with
diabetes mellitus and microalbuminuria [50], and is currently
Figure 3. Peritoneal CCN2, TGFb1, and VEGF gene expression in encapsulating peritoneal sclerosis. Gene expression of CCN2 (3A),
TGFb1 (3B), and VEGF (3C) in peritoneum of patients with encapsulating peritoneal sclerosis (EPS) compared to peritoneal dialysis (PD) and non-PD
patients without EPS. Mean 6SD. * P,0.001 versus PD patients without EPS. ** P,0.05 versus PD patients without EPS. # P,0.001 versus PD
patients without EPS.
doi:10.1371/journal.pone.0112050.g003
Figure 4. Peritoneal CCN2 protein expression in encapsulating
peritoneal sclerosis. Immunohistochemistry for CCN2 in representa-
tive peritoneal biopsies of three peritoneal dialysis (PD) patients shows
no significant staining (upper panel). In representative peritoneal
biopsies of three patients with encapsulating peritoneal sclerosis (EPS),
strong CCN2 staining is observed (middle panel). At higher
magnification (lower panel), it is seen that CCN2 protein is mainly
localized in endothelial cells (arrows) and interstitial fibroblasts
(asterisks).
doi:10.1371/journal.pone.0112050.g004
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being tested in patients with idiopathic pulmonary fibrosis and
liver fibrosis. Finally, it has recently been shown that CCN3,
another CCN family member, works in a yin/yang manner to
regulate CCN2 production and activity. In cell-based models of
renal and skin disease, TGFb1 and platelet-derived growth factor
stimulated CCN2 activity and collagen deposition leading to
progression of fibrosis. Exogenous CCN3 was able to block these
effects [51,52]. These findings with CCN3 have provided the basis
for a third CCN2-targeted biological currently being developed as
an anti-fibrosis therapy. Collectively, these data suggest that the
application one or more of these biologicals, perhaps by the
intraperitoneal route, may also be feasible in the PD patient to
prevent or block progression of EPS.
Early detection of the development of EPS would be very
important, especially in view of the potential preventive or
therapeutic interventions. CCN2 is locally produced and present
in dialysate [38,53] and appears to correlate with the dialysate-to-
plasma ratio of creatinine [38]. In addition, a positive relation was
reported between the CCN2 concentration in PD fluid after an
overnight dwell and PD duration in a cross-sectional study, albeit
with a very low R2 value of 0.07. However, whether longitudinal
follow-up of peritoneal CCN2 concentration or appearance rate
has any value in predicting the development of peritoneal fibrosis
or sclerosis remains to be studied. In view of the prominent
overexpression of VEGF in EPS biopsies in our study and that of
Braun et al. [44], it is disappointing that the longitudinally
obtained dialysate VEGF concentration could not predict the
development EPS in patients on PD [54], which makes it difficult
to apply any preventive anti-VEGF therapy. Finally, TGFb1 is
also not a useful diagnostic marker for EPS as only an inactive
soluble form is present in peritoneal effluent [55,56]. To date, no
study has measured CCN2 levels in ascites or in peritoneal effluent
of EPS patients. We obtained ascites in 7 of the 12 EPS patients
and found considerably higher CCN2 concentrations in ascites of
EPS patients than in the effluent of non-EPS PD patients. In
contrast, plasma concentrations of CCN2 did not differ. These
high CCN2 levels in ascites in combination with peritoneal CCN2
overexpression agree with a locally driven response in EPS.
However, we cannot rule out the effect of a difference in dwelling
time on the local CCN2 levels in these groups. While the dwelling
time in non-EPS patients was four hours, the ‘‘dwelling time’’ of
ascites in our EPS patients was, for obvious reasons, unknown but
undoubtedly longer than that.
In conclusion, peritoneal CCN2, TGFb1, and VEGF expres-
sion are markedly increased in the peritoneal membrane of PD
patients with EPS. Whether this increased expression is a late,
sudden phenomenon induced by a second hit or a more gradual
process correlated with PD duration remains to be determined. As
CCN2 appears an attractive target for antifibrotic therapy,
prospective, longitudinal studies are needed to determine whether
the dialysate CCN2 concentration or appearance rate combined
with peritoneal transport studies can predict the development of
peritoneal fibrosis and sclerosis.
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